Skip to main content

Mylan Value Stock - Dividend - Research Selection


ISIN: NL0011031208, WKN: A14NYH

Market price date: 30.11.-0001
Market price: 0,00 USD

Mylan Fundamental data and company key figures of the share

Annual reports in USD
Key figures 01-03-2020
Cash flow
Net operating cash flow 1.803.700.000
Capital Expenditures -213.200.000
Free cash flow 1.590.499.968
Balance sheet
Total Equity 11.883.800.000
Liabilities & Shareholders equity 31.255.500.000
Income statement
Net income 16.800.000
Eps (diluted) 0,030
Diluted shares outstanding 560.000.000
Net sales/revenue 11.500.500.000

Fundamental ratios calculated on: 30-11--0001

Key figures 30-11--0001
Cash flow
P/C 0,00
P/FC 0,00
Balance sheet
Income statement
Div. Yield0,00%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization8.881.600.512,00 USD
IndicesMSCI World Index
Raw Data Source
Stock Split

Description of the company

Mylan Inc. (Mylan) is a fully integrated global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. Mylan has two segments:Generics and Specialty. Its generic pharmaceutical business is conducted primarily in the United States and Canada (collectively, North America); Europe, the Middle East, and Africa (collectively, EMEA); and India, Australia, Japan and New Zealand (collectively, Asia Pacific). Its API business is conducted through Mylan Laboratories Limited (Mylan India), which is included within the Asia Pacific region in its Generics Segment. The Company's pharmaceutical business is conducted by Mylan Specialty L.P. (Mylan Specialty). Mylan provides products to customers in approximately 140 countries and territories. In December 2013, In December 2013, the Company announced that it has completed the acquisition of the Agila injectables businesses from Strides Arcolab Ltd.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


Consumer Spending, E-Commerce, and the Business of Lodging

In this week's episode of Motley Fool Money, Motley Fool analyst Olivia Zitkus and Motley Fool contributor Keith Speights, along with host Chris Hill, discuss a new wave of biosimilar drugs and the challenges (and opportunities for investors) that they present. Also, Motley Fool